Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Dosage
1471 Sodium Tetradecyl Sulphate 3 % Injection C05BB04183P3002XX A* Sclerotherapy of oesophageal varices, haemorrhoids and varicose veins 0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid, several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment
1472 Sodium Thiosulphate 10-20% Solution D01AE00181L9901XX C Fungicides. For the treatment of pityriasis versicolor Apply to all affected parts of the body and face with a brush after a bath once daily or twice daily or 3 times daily
1473 Sodium Thiosulphate 500 mg/ml Injection V03AB06181P3001XX B For cyanide poisoning Adult: To be given after 300 mg of sodium nitrite has been admin over 5-20 min: 12.5 g of sodium thiosulfate (50 ml of a 25% solution or 25 ml of a 50% solution) given over 10 min. Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses. Child: To be given after 4-10 mg/kg of sodium nitrite (max: 300 mg) has been admin: 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.
1474 Sodium Valproate 200 mg Tablet N03AG01520T1001XX B i. Epilepsy ii. Treatment and prevention of mania associated with bipolar disorders i. Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may be increased by 200 mg at 3-day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg 20 mg/kg/day, in severe cases the dose may be increased provided plasma concentration can be monitored. ii. Treatment and prevention of mania associated with bipolar disorders: Adults: The recommended initial dose is 1000mg/day. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose, which produces the desired clinical effects. The recommended maintenance dosage for the treatment of bipolar disorder is between 1000mg and 2000mg daily. In exceptional cases, the dose may be increased to not more than 3000mg daily.
1475 Sodium Valproate 200 mg/5 ml Syrup N03AG01520L9001XX B Epilepsy ADULT: Initially 600 mg/day; dose may be increased by 200 mg at 3-day intervals to max 2500 mg/day. Usual maintenance dose: 1000-2000 mg/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg, 20 mg/kg/day. Severe cases: 50 mg/kg daily
1476 Sodium Valproate 400 mg Injection N03AG01520P4001XX B Status epilepticus ADULT and CHILD above 10 years: 10 to 15 mg/kg/day IV, may increase 5 to 10 mg/kg/week to achieve optimal clinical response (Maximum 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL)
1477 Solifenacin Succinate 5 mg Tablet G04BD08000T1001XX A* Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome. 5mg od. Dose can be increased to 10mg if necessary.
1478 Somatropin 10 mg (30IU) Injection H01AC01000P5002XX A* To be used in children for: i) Growth failure due to inadequate endogenous growth hormone. ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome). iii) Growth failure in short children born small gestational age (SGA) To be used in adult for: i) Pronounced growth hormone deficiency (GHD) in known hypothalamic-pituitary disease. ii) Childhood onset growth hormone insufficiency. i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM. ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC. iii) 0.035 mg/kg/day or 1 mg/m2/day SC For adult: a) Replacement therapy: The dosage must be adjusted to the need of the individual patient. b) Childhood-onset GHD: The recommended dose to restart is 0.2?0.5 mg/day with subsequent dose adjustment on the basis of IGF-I concentration determination. c) Adult-onset GHD: It is recommended to start treatment with a low dose 0.1?0.3 mg/day and to increase the dosage gradually at monthly intervals in order to meet the need of the individual patient. Serum IGF-I can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement, are under-treated while men are over-treated. Dose requirements decline with age. Maintenance dosages vary from person to person, but seldom exceed 1.0 mg/day (equal to 3 IU/day).
1479 Somatropin 12 mg (36IU) Injection H01AC01000P3002XX A* i) Growth failure due to inadequate endogenous growth hormone ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii) Growth failure in short children born small gestational age (SGA) i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
1480 Somatropin 5mg (15IU) Injection H01AC01000P3004XX A* To be used in children for: i) Growth failure due to inadequate endogenous growth hormone. ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome). iii) Growth failure in short children born small gestational age (SGA) To be used in adult for: i) Pronounced growth hormone deficiency (GHD) in known hypothalamic-pituitary disease. ii) Childhood onset growth hormone insufficiency. i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC For adult: Indication ii): a) Replacement therapy: The dosage must be adjusted to the need of the individual patient. b) Childhood-onset GHD: The recommended dose to restart is 0.2?0.5 mg/day with subsequent dose adjustment on the basis of IGF-I concentration determination. c) Adult-onset GHD: It is recommended to start treatment with a low dose 0.1?0.3 mg/day and to increase the dosage gradually at monthly intervals in order to meet the need of the individual patient. Serum IGF-I can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement, are under-treated while men are over-treated. Dose requirements decline with age. Maintenance dosages vary from person to person, but seldom exceed 1.0 mg/day (equal to 3 IU/day).
1481 Somatropin 8 mg (24IU) Injection H01AC01000P3003XX A* i) Growth failure due to growth hormone insufficiency ii)Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii)Growth failure in short children born small gestational age(SGA) i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
1482 Sotalol HCl 160 mg Tablet C07AA07110T1002XX A* Ventricular tachyarrythmias Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses.
1483 Sotalol HCl 80 mg Tablet C07AA07110T1001XX A* Ventricular tachyarrythmias Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses.
1484 Spironolactone 25 mg Tablet C03DA01000T1001XX B Oedema and ascites in cirrhosis of the liver, congestive heart failure ADULT: 100 - 200 mg daily in divided doses. Increase to 400 mg if required. CHILD: initially 3 mg/kg daily in divided doses
1485 Stavudine 30 mg, Lamivudine 150 mg & Nevirapine 200 mg Tablet J05AR07964T1001XX A/KK Fixed dose triple therapy for treatment of HIV infection in adults once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice daily and have demonstrated adequate tolerability to nevirapine SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice daily
1486 Stavudine 40 mg, Lamivudine 150 mg & Nevirapine 200 mg Tablet J05AR07964T1002XX A* Fixed dose triple therapy for treatment of HIV infection in adults once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice daily and have demonstrated adequate tolerability to nevirapine SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice daily
1487 Streptokinase 1,500,000 IU Injection B01AD01000P4001XX A* Acute myocardial infarction, acute pulmonary embolism Myocardial infarction: 1,500,000 units over 30 - 60 minutes. Pulmonary embolism: 250,000 units by IV infusion over 30 minutes, then 100,000 units every hour for up to 12-72 hours with monitoring of clotting factors
1488 Streptomycin Sulphate 1 g Injection J01GA01183P4001XX B Tuberculosis ADULT: 15 mg/kg daily; max: 1 g daily. Reduce max daily dose to 500-750 mg in patients >40 yr. As part of an intermittent therapy: 25-30 mg/kg/day 2-3 times/wk; max: 1.5 g/dose. Not >120 g over the course of treatment should be given unless there are no other treatment options. Child: 20-40 mg/kg (max: 1 g) daily or 25-30 mg/kg (max: 1.5 g) 2-3 times wkly.
1489 Strontium Ranelate 2 g Granules M05BX03000F1001XX A* Treatment of postmenopausal osteoporosis to reduce risk of vertebral and hip fractures when biphosphonates are contraindicated or not tolerated 2 g sachet once daily
1490 Succindialdehyde 11% & Dimethoxytetrahydrofuran 3% V07AV00000L9907XX A High level disinfection for endoscopes, ultrasonicprobes, anaesthesia equipment etc Immersion time is based on manufacturers recommendation
1491 Sucralfate 1 g Tablet A02BX02000T1001XX A i) Benign gastric and duodenal ulceration ii) Stress ulcer prophylaxis i) 2 g twice daily or 1 g 4 times daily for 4-6 weeks or in resistant cases up to 12 weeks (maximum 8 g daily) ii) 1 g 6 times daily (maximum 8 g daily). CHILD not recommended
1492 Sugammadex 100 mg/ml Injection V03AB35000P3001XX A* Indicated for reversal of neuromuscular blockade induced by rocuronium and vecuronium in selective patient group: obese, elderly, underlying cardiovascular disease. For pediatric population, sugammadex is recommended for routine reversal 2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of second twitch tension of the train-of-four (T2). 4 mg/kg sugammadex is recommended if recovery has reached at least 1- 2 post-tetanic counts (PTC). For immediate reversal following administration of rocuronium a dose of 16 mg/kg sugammadex is recommended
1493 Sulfadoxine 500 mg and Pyrimethamine 25 mg Tablet P01BD51981T1001XX B Treatment of Plasmodium falciparum malaria in patients in whom chloroquine resistance is suspected and malaria prophylaxis for travellers to areas where chloroquine-resistant malaria is endemic Chloroquine resistant falciparum malaria acute attack Adult: Per tab contains pyrimethamine 25 mg and sulfadoxine 500 mg: 2-3 tabs as a single dose. Do not repeat for at least 7 days. Child: Pyrimethamine 25mg + Sulfadoxine 500mg (Tablet): <2 yr (5-10 kg): 1/2 (half) tab as a single dose; 2-5 yr (>10-20 kg): 1 tab as a single dose; 5-10 yr (< 20-30 kg): 1 1/2 (one and half) tab as a single dose; 10-14 yr (> 30-45 kg): 2 tab as a single dose. Do not repeat for at least 7 days. Renal impairment: Dose reduction may be needed. Severe: contra-indicated. Hepatic impairment: Dose reduction may be needed. Severe: contra-indicated.
1494 Sulphamethoxazole 200 mg & Trimethoprim 40 mg/5ml Suspension J01EE01961L8001XX B Infections caused by susceptible pathogens Mild to moderate infections: more than 2months: 8 - 12mg Trimethoprim/kg/day divided every 12hours. Serious Infections: 15-20mg Trimethoprim/kg/day divided every 6hours.
1495 Sulphamethoxazole 400 mg & Trimethoprim 80 mg Injection J01EE01961P3001XX A i) Severe or complicated infections when oral therapy is not feasible ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patients i) ADULT: 960 mg twice daily increased to 1.44 g twice daily in severe infections. CHILD: 36 mg/kg daily in 2 divided doses increased to 54 mg/kg/day in severe infections ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day PO/IV infusion in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg
1496 Sulphamethoxazole 400 mg & Trimethoprim 80 mg Tablet J01EE01961T1001XX B i) Severe or complicated infections due to susceptible infection ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patients i) ADULT: 1 - 3 tablets twice daily ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD; 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg
1497 Sulphur 2% & Salicylic Acid 2% Cream D10AB02951G1001XX C Acne vulgaris and seborrhoeic dermatitis When used in scalp disorders, a small amount of cream should be rubbed gently into the roots of the hair. When used in skin disorders, the cream should be applied sparingly to the affected area. Apply once daily or until noticeable improvement, then once or twice a week
1498 Sulpiride 200 mg Tablet N05AL01000T1001XX B Acute and chronic schizophrenia, chronic delusional psychoses 200-400 mg twice daily; 800 mg daily in predominantly negative symptoms and 2.4 g daily in mainly positive symptoms. Elderly, lower initial dose; increased gradually according to response. Child under 14 years not recommended
1499 Sumatriptan 100 mg Tablet N02CC01000T1002XX A/KK Treatment of acute migraine attacks 50 mg per attack and not more than 300 mg daily
1500 Sumatriptan 50 mg Fast Disintegrating Tablet N02CC01000T5001XX A Treatment of acute migraine attacks 50 mg per attack and not more than 300 mg daily

Halaman-halaman